Academic journal article Issues in Law & Medicine

Epidemiologic and Molecular Relationship between Vaccine Manufacture and Autism Spectrum Disorder Prevalence

Academic journal article Issues in Law & Medicine

Epidemiologic and Molecular Relationship between Vaccine Manufacture and Autism Spectrum Disorder Prevalence

Article excerpt

A worldwide autism epidemic is copiously established by the number of peer reviewed articles on the subject, including the observations from numerous institutions that de novo genetic insertions and mutations are excessive in children with autism.1 Autism disorder (AD), a subset of Autism Spectrum Disorder (ASD), is a neurological and developmental disorder whose symptoms usually appear within the first three years of life.2 The autism epidemic obviously creates significant public health burden and demands critical assessment of environmental factors that may trigger this epidemic. A previous publication from our group focused on overlooked, universally introduced environmental factors, including human fetal and retroviral contaminants in childhood vaccines, advancing paternal age and changes in diagnostic criteria. As the US Environmental Protection Agency (EPA) requires, discovery of potential environmental triggers for autism requires statistical assessment to identify birth year change points for autism spectrum disorder prevalence. Iterative fitting algorithms identified 1980.8, 1988.4 and 1996.5 as "changepoint" years for the United States AD prevalence,3 in substantiation of a report from the Environmental Protection Agency (EPA) that identified a 1988 worldwide AD change point.4 Additionally, AD birth year changepoints for the United Kingdom, Western Australia and Denmark are calculated to be 1987, 1990.4 and 1987.5, respectively.3 These statistically calculated AD changepoints do not correspond to changepoints that would be predicted based on printing schedules for revisions to the Diagnostic and Statistical Manual (DSM), and therefore DSM revisions cannot be the primary environmental or sociological trigger responsible for current AD prevalence. Advancing paternal age is currently a favored explanation for the worldwide autism epidemic. However, linear regression analysis for the US and Western Australia data revealed no relationship between paternal age and AD for any specific birth year.3

In UK and some Scandinavian countries it is notable that there was a significant decline in MMR immunization coverage during discrete years hypothetically triggered by a scare following Andrew Wakefield's 1998 publication5 that suggested MMR immunization and autistic regression were linked, but clearly not due to a failure to report immunizations.6'8 Since we detected a relationship between MMR and AD/ASD prevalence in our previous study, the observation that MMR coverage dropped acutely in UK and Scandinavian countries during discrete years raises the question of whether MMR coverage impacted AD/ASD prevalence in these countries during this same time period .

Utilizing human fetal cell lines to manufacture childhood vaccines leaves behind residual human DNA as well as human endogenous retrovirus K (HERVK) fragments in the final vaccine products we inject into our children. Mammalian cells take up same species extracellular DNA fragments via receptor mediated endocytosis. Uptake is most efficient at low concentrations of extracellular DNA4 and peaks 2 hours after addition of the DNA fragments to cell culture.10 In the extracellular concentration range of 0.1 to 7 pM, oligonucleotides (small bits of nucleic acids) readily enter cultured cells through receptor mediated uptake,11'13 reaching intracellular and nuclear11'14'16 concentrations which equal or exceed that of the extracellular medium within 2-4 hours.1. Empirical experiments have shown that addition of placental DNA fragments of 500 base pairs in length contributed approximately 4% of a cell's genomic content per hour of incubation roughly 40-50% of fragmented DNA added to cell culture will be taken up by a cell and 10-20% of the added DNA will be delivered to the nucleus, demonstrating the rapidity with which DNA can enter a cell.9,18 Current FDA guidance is that the level of residual cell-substrate DNA should be less than 10 ng per vaccine dose with a median DNA size of 200 base pairs or lower. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.